Zacks: Analysts Anticipate Sarepta Therapeutics Inc (SRPT) to Post -$0.47 EPS

Equities analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce earnings of ($0.47) per share for the current quarter, Zacks reports. Nine analysts have provided estimates for Sarepta Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($1.24). Sarepta Therapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a positive year over year growth rate of 59.1%. The company is expected to issue its next quarterly earnings report on Wednesday, July 18th.

On average, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.61) to ($0.90). For the next year, analysts forecast that the business will report earnings of $0.15 per share, with EPS estimates ranging from ($0.88) to $1.18. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The firm had revenue of $64.60 million for the quarter, compared to the consensus estimate of $65.31 million. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. The company’s revenue for the quarter was up 295.3% compared to the same quarter last year.

Several equities research analysts have commented on the company. WBB Securities reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Wednesday, June 20th. Nomura boosted their target price on Sarepta Therapeutics from $131.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, June 21st. Robert W. Baird reissued an “outperform” rating and issued a $202.00 target price (up from $120.00) on shares of Sarepta Therapeutics in a report on Thursday, June 21st. Needham & Company LLC boosted their target price on Sarepta Therapeutics from $109.00 to $204.00 and gave the stock a “buy” rating in a report on Wednesday, June 20th. Finally, SunTrust Banks boosted their target price on Sarepta Therapeutics to $176.00 and gave the stock a “buy” rating in a report on Friday, June 22nd. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $147.98.

Shares of Sarepta Therapeutics traded down $0.31, hitting $137.73, during mid-day trading on Friday, according to MarketBeat. 656,496 shares of the stock traded hands, compared to its average volume of 1,646,908. The company has a quick ratio of 12.28, a current ratio of 13.37 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 52 week low of $32.80 and a 52 week high of $176.50. The firm has a market capitalization of $9.04 billion, a PE ratio of -83.93 and a beta of 1.34.

In other news, Director Richard Barry sold 75,000 shares of the business’s stock in a transaction on Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total value of $9,775,500.00. Following the completion of the transaction, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Clarus Wealth Advisors purchased a new stake in Sarepta Therapeutics during the second quarter valued at $124,000. Arrowstreet Capital Limited Partnership purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at $217,000. Bayesian Capital Management LP purchased a new stake in Sarepta Therapeutics during the first quarter valued at $221,000. Zeke Capital Advisors LLC purchased a new stake in Sarepta Therapeutics during the first quarter valued at $241,000. Finally, ETRADE Capital Management LLC purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at $247,000. Hedge funds and other institutional investors own 86.27% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply